Letter by McCaw et al Regarding Article, "The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease".
Circulation
; 143(1): e1-e2, 2021 01 05.
Article
em En
| MEDLINE
| ID: mdl-33378233
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Doenças Vasculares
/
Rivaroxabana
Limite:
Humans
Idioma:
En
Revista:
Circulation
Ano de publicação:
2021
Tipo de documento:
Article